Rodman & Renshaw FDA Diabetes Panel Wrap Up Call

Title: Rodman & Renshaw FDA Diabetes Panel Wrap Up Call
Artist: Zangani Investor Community(TM)
Length: 58:05 minutes (13.3 MB)
Format: Mono 22kHz 32Kbps (CBR)

Rodman & Renshaw and Close Concerns present the latest in a series of medical expert conference calls

The call features David G. Orloff, MD, Medical Director / Medical & Regulatory Affairs of Medpace, Inc.

Senior Biotechnology Analysts:

Michael G. King, Jr.

Thomas Shrader, Ph.D., CFA

Vernon Bernardino

Close Concerns, Inc.:

Kelly L. Close, Principal
(www.closeconcerns.com)

Dr. David Orloff is Executive Director, Regulatory Affairs at Medpace. He is the immediate past director of the Division of Metabolism and Endocrinology Products within the Center for Drug Evaluation and Research (CDER) of the FDA. Dr. Orloff is an endocrinologist and has 11 years of regulatory experience, with major foci in diabetes, obesity, and lipid metabolism. He has research experience in molecular and cellular biology and clinical endocrinology at the National Institute of Child Health and Human Development (NICHD), the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH). Dr. Orloff was a consultant to the National Cholesterol Education Program, Adult Treatment Plan III, and is an advisor to multiple pharmaceutical companies working in the metabolism and diabetes fields. Dr. Orloff is a key member of Medpace’s staff regarding regulatory strategy and endocrinology expertise.

For more information, please contact your Rodman & Renshaw, LLC sales representative or Michael King directly at (212) 430-1750.